Literature DB >> 28280247

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Enfu Hui1, Jeanne Cheung2, Jing Zhu2, Xiaolei Su1, Marcus J Taylor1, Heidi A Wallweber2, Dibyendu K Sasmal3, Jun Huang3, Jeong M Kim2, Ira Mellman4, Ronald D Vale5.   

Abstract

Programmed cell death-1 (PD-1) is a coinhibitory receptor that suppresses T cell activation and is an important cancer immunotherapy target. Upon activation by its ligand PD-L1, PD-1 is thought to suppress signaling through the T cell receptor (TCR). By titrating PD-1 signaling in a biochemical reconstitution system, we demonstrate that the co-receptor CD28 is strongly preferred over the TCR as a target for dephosphorylation by PD-1-recruited Shp2 phosphatase. We also show that CD28, but not the TCR, is preferentially dephosphorylated in response to PD-1 activation by PD-L1 in an intact cell system. These results reveal that PD-1 suppresses T cell function primarily by inactivating CD28 signaling, suggesting that costimulatory pathways play key roles in regulating effector T cell function and responses to anti-PD-L1/PD-1 therapy.
Copyright © 2017, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28280247      PMCID: PMC6286077          DOI: 10.1126/science.aaf1292

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  47 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation.

Authors:  W Zhang; J Sloan-Lancaster; J Kitchen; R P Trible; L E Samelson
Journal:  Cell       Date:  1998-01-09       Impact factor: 41.582

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling.

Authors:  F Pagès; M Ragueneau; R Rottapel; A Truneh; J Nunes; J Imbert; D Olive
Journal:  Nature       Date:  1994-05-26       Impact factor: 49.962

6.  Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Authors:  Frann Bennett; Deborah Luxenberg; Vincent Ling; I-Ming Wang; Kim Marquette; David Lowe; Nighat Khan; Geertruida Veldman; Kenneth A Jacobs; Viia E Valge-Archer; Mary Collins; Beatriz M Carreno
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

7.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

8.  Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4.

Authors:  L E Marengère; P Waterhouse; G S Duncan; H W Mittrücker; G S Feng; T W Mak
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

9.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

10.  In vitro membrane reconstitution of the T-cell receptor proximal signaling network.

Authors:  Enfu Hui; Ronald D Vale
Journal:  Nat Struct Mol Biol       Date:  2014-01-26       Impact factor: 15.369

View more
  474 in total

Review 1.  The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.

Authors:  Arabella Young; Zoe Quandt; Jeffrey A Bluestone
Journal:  Cancer Immunol Res       Date:  2018-12       Impact factor: 11.151

2.  Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.

Authors:  Bo Ryeong Lee; Sehyun Chae; Jihyun Moon; Myeong Joon Kim; Hankyu Lee; Hyuk Wan Ko; Byoung Chul Cho; Hyo Sup Shim; Daehee Hwang; Hye Ryun Kim; Sang-Jun Ha
Journal:  JCI Insight       Date:  2020-07-23

3.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Authors:  John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 4.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 5.  Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Authors:  A Mitsuhashi; Y Okuma
Journal:  Clin Transl Oncol       Date:  2018-01-08       Impact factor: 3.405

Review 6.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

7.  Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).

Authors:  Despoina Koumantou; Eilon Barnea; Adrian Martin-Esteban; Zachary Maben; Athanasios Papakyriakou; Anastasia Mpakali; Paraskevi Kokkala; Harris Pratsinis; Dimitris Georgiadis; Lawrence J Stern; Arie Admon; Efstratios Stratikos
Journal:  Cancer Immunol Immunother       Date:  2019-06-20       Impact factor: 6.968

8.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

Review 9.  Cancer vaccines: translation from mice to human clinical trials.

Authors:  Hoyoung Maeng; Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

10.  EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity.

Authors:  Michael Peled; Matthew A Dragovich; Kieran Adam; Marianne Strazza; Anna S Tocheva; Irving E Vega; Adam Mor
Journal:  J Immunol       Date:  2018-10-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.